Market capitalization | $1.39m |
Enterprise Value | $13.04m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-23.39m |
Free Cash Flow (TTM) Free Cash Flow | $-21.66m |
Cash position | $3.06m |
As a Free StocksGuide user, you can view scores for all 6,885 stocks worldwide.
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -2.80 -2.80 |
1%
1%
|
|
EBITDA | -21 -21 |
10%
10%
|
EBIT (Operating Income) EBIT | -23 -23 |
9%
9%
|
Net Profit | -25 -25 |
7%
7%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kiromic Biopharma, Inc. operates as a biotechnology company, which engages in the development of cancer engineered immunotherapies. Its technologies include Intelligent Immunotherapy, Diamond AI, CancerSplice, ABBIE, and CAR-T Proprietary Binder Technology. The company was founded by Maurizio Chiriva-Internati and Scott Dahlbeck on August 6, 2006 and is headquartered in Houston, TX.
Head office | United States |
CEO | Pietro Bersani |
Employees | 35 |
Founded | 2006 |
Website | www.kiromic.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.